Cure8 research brief
Faster, more accurate chart abstraction could speed IBD research and quality monitoring while reducing reviewer workload and errors, which may help registries and studies that rely on manually curated EHR data.
Clinicians and researchers who build or maintain IBD registries or research databases; clinical informatics teams evaluating AI-assisted abstraction; patients and advocates interested in how EHR data are used for IBD research.
The authors developed a locally deployed, source-linked extraction pipeline and a source-aware user interface so clinicians could review and correct model outputs.
Time savings and accuracy gains were largest for variables that required synthesizing information across multiple notes; for high-salience variables (straightforward fields) performance was similar between manual and assisted review.
The study released the pipeline and interface as open-source tools, aiming to provide a reproducible template for scalable clinical database curation and transparent AI methods in research. The study is reported at the abstract level from the journal article; Cure8 did not independently verify underlying patient-level data or downstream database use.
This classification is based on the journal abstract (structured content depth: abstract). The reported results come from a controlled user study with a small number of clinician annotators; the abstract-level report does not replace a full methods and results read for implementation decisions.
The tools are open-source but local deployment, validation, and privacy safeguards will matter for real-world use.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This bibliometric analysis summaries recent Spanish research activity in IBD, showing where work is concentrated, the mix of clinical versus basic/translational studies, and gender representation in scientific...
Clinical trials expand treatment options and are how new IBD therapies are tested and approved. Low enrollment can delay access to future treatments for Crohn’s and ulcerative colitis.
A new bispecific antibody program (TL1A x IL-23p19) advancing toward patient trials could expand treatment options for people with ulcerative colitis and Crohn’s disease if later-stage trials confirm safety and efficacy....
